Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip and Microfluidics World Congress 2022

Abraham Lee's Biography

Abraham Lee, Chancellor’s Professor, Biomedical Engineering & Director, Center for Advanced Design & Manufacturing of Integrated Microfluidics, University of California-Irvine

Abraham (Abe) P. Lee is Chancellor's Professor in the Biomedical Engineering (BME) Department with a courtesy appointment in Mechanical and Aerospace Engineering (MAE) at the University of California, Irvine. He is the Director of the NSF I/UCRC “Center for Advanced Design & Manufacturing of Integrated Microfluidics” (CADMIM). Prior to UCI, he was at the National Cancer Institute and a program manager in the Microsystems Technology Office at DARPA (1999-2001). Dr. Lee’s lab focuses on developing active integrated microfluidics and droplet microfluidic platforms. These platforms are applied to point-of-care and molecular diagnostics, “smart” nanomedicine for early detection and treatment, single cell processing and analysis, and tissue engineering and cell-based therapeutics. His research has contributed to the founding of several start-up companies. Dr. Lee serves as an associate editor for the Lab on a Chip journal and he is also an advisor to companies and government agencies. He owns 42 issued US patents and is author of over 100 journals articles. Professor Lee was awarded the 2009 Pioneers of Miniaturization Prize and is an elected fellow of the National Academy of Inventors, the American Institute of and Medical and Biological Engineering and the American Society of Mechanical Engineers.

Abraham Lee Image

Vein-to-Vein Microfluidic Engineering for Cell Therapies

Monday, 12 December 2022 at 15:30

Add to Calendar ▼2022-12-12 15:30:002022-12-12 16:30:00Europe/LondonVein-to-Vein Microfluidic Engineering for Cell TherapiesLab-on-a-Chip and Microfluidics World Congress 2022 in Long Beach, CaliforniaLong Beach,

Adoptive cell therapy (ACT) involves the processing of blood from a donor to isolate T lymphocytes (T cells) for genetic manipulation followed by reinfusion of the cells into patients. The genetic manipulation is carried out by inserting genetic coding material (e.g. DNA, mRNA) into the T cells to express chimeric antigen receptors to target biomarkers of cancer cells and trigger an activated immune response towards the tumor of interest. If the cells are from the same patient it is considered autologous and if from a different donor it is allogenic. Also, different immune cells can be used in addition to T cells, e.g., NK cells, dendritic cells, and CD4+ helper T cells.  This process that starts from blood from the vein of one person and ends with specialized engineered cells delivered to the vein of a patient includes multiple tedious and costly steps, and can require a long time that the patient may not have. Microfluidics techniques are being developed that can address all steps of this cell manufacturing process, including cell harvesting, cell isolation, cell expansion, and cell transfection, and has the potential to drastically reduce cost and processing times.  In this presentation, I will introduce our microfluidic platforms based on the lateral cavity acoustic transducer for processing blood samples, isolating T cells, transfecting T cells, and finally expanding T cells to scale up for treatment. The LCAT device has been used to isolate leukocytes from whole blood. In particular, I will introduce the acoustic electric shear orbiting poration (AESOP) device that is able to uniformly deliver genetic cargo dosage into a large population of cells simultaneously in comparison with conventional transfection techniques. I will also introduce an another microfluidic method to construct artificial antigen presenting cells for T cell activation.

Add to Calendar ▼2022-12-12 00:00:002022-12-14 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics World Congress 2022Lab-on-a-Chip and Microfluidics World Congress 2022 in Long Beach, CaliforniaLong Beach,